Islamabad, Dec 16: Citi Pharma Ltd. (PSX: CPHL) has announced its entry into the direct marketing sector, starting January 1, 2025. This strategic shift aims to transition from its traditional focus on serving hospitals and institutions, along with its Active Pharmaceutical Ingredient (API) business, to directly delivering high-quality pharmaceutical products to the public across Pakistan.
Aligning with Vision 2030: From “Care to Cure”
In a notice to the Pakistan Stock Exchange (PSX) on Monday, Citi Pharma outlined this move as part of its 2030 Vision: From “Care to Cure.” The initiative underscores its commitment to improving access to affordable and innovative healthcare solutions for all Pakistanis.
The company has appointed industry veteran Aamir Shahzad as Chief Commercial Officer (CCO) to lead the effort. With 28 years of experience in renowned pharmaceutical companies such as Barret Hodgson and Hilton Pharma, Shahzad’s mission is to position Citi Pharma as Pakistan’s leading pharmaceutical company by 2030. He also aims to expand Citi Pharma’s global footprint, offering cost-effective and advanced healthcare solutions internationally.
Diverse Product Portfolio
Citi Pharma’s new product lineup will feature a wide range of general formulations, including:
- Antibiotics for bacterial infections.
- Cardiovascular and anti-diabetic drugs for chronic conditions.
- Analgesics and antipyretics for pain and fever management.
- Respiratory treatments for asthma and related conditions.
In the biotechnology space, the company will focus on advanced treatments, including:
- Insulin and other diabetes management products.
- Vaccines for infectious diseases.
- Monoclonal antibodies for cancer, arthritis, and autoimmune disorders.
- Recombinant proteins for rare and complex diseases.
Commitment to Oncology
Citi Pharma is determined to make cancer treatment more accessible and affordable, aiming to bring hope to those battling life-threatening conditions.
This comprehensive strategy positions Citi Pharma to emerge as a leader in Pakistan’s pharmaceutical industry, delivering innovative solutions across the healthcare spectrum.
